Letter From the Editors
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
Oncology Spectrums Volume 2 No. 8
-
Oncology Ethics Forum
Ethical Perspectives on Oncology Care
By Terri Maxwell, RN, MSN, AOCN
-
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
-
Development of Antagonists of the Platelet-Derived Growth Factor Receptor Family
By Neill A. Giese, PhD, Nathalie A. Lokker, PhD, Jin-Chen Yu, PhD, Kenji Matsuno, PhD, Michio Ichimura, PhD, Shoji Oda, PhD, Robert Scarborough, PhD, and Anjali Pandey, PhD
-
STI571: A Sea Change in Cancer Therapeutics or a One Time Event?
By Brian J. Druker, MD
-
Pharmacy Practice
The Role of Chemoprotectants in Cancer Supportive Care
By Masha S. H. Lam, PharmD, and Robert J. Ignoffo, PharmD, FASHP
-
Development of STI571 and Its Use in Chronic Myelogenous Leukemia and Other Malignancies
By Michael J. Mauro, MD, Michael E. O’Dwyer, MD, and Brian J. Druker, MD
-
Understanding the Genotoxicity of Tamoxifen?
By David H. Phillips, DSc, MRCPath